[HAN, Bing 韩冰, HAN, Bing 韩冰, ZHAO, Jiaqing 赵家庆, HAN, Bing 韩冰, ZHAO, Jiaqing 赵家庆, QIAN, Kejun 钱科军, HAN, Bing 韩冰, ZHAO, Jiaqing 赵家庆, QIAN, Kejun 钱科军, SHANG, Xuewei 尚学伟, HAN, Bing 韩冰, ZHAO, Jiaqing 赵家庆, QIAN, Kejun 钱科军, SHANG, Xuewei 尚学伟, ZHANG, Lingtao 张令涛, HAN, Bing 韩冰, ZHAO, Jiaqing 赵家庆, QIAN, Kejun 钱科军, SHANG, Xuewei 尚学伟, ZHANG, Lingtao 张令涛, DING, Hongen 丁宏恩, HAN, Bing 韩冰, ZHAO, Jiaqing 赵家庆, QIAN, Kejun 钱科军, SHANG, Xuewei 尚学伟, ZHANG, Lingtao 张令涛, DING, Hongen 丁宏恩, LI, Chun 李春, HAN, Bing 韩冰, ZHAO, Jiaqing 赵家庆, QIAN, Kejun 钱科军, SHANG, Xuewei 尚学伟, ZHANG, Lingtao 张令涛, DING, Hongen 丁宏恩, LI, Chun 李春, ZHAO, Lin 赵林, HAN, Bing 韩冰, ZHAO, Jiaqing 赵家庆, QIAN, Kejun 钱科军, SHANG, Xuewei 尚学伟, ZHANG, Lingtao 张令涛, DING, Hongen 丁宏恩, LI, Chun 李春, ZHAO, Lin 赵林, SUN, Pai 孙湃, HAN, Bing 韩冰, ZHAO, Jiaqing 赵家庆, QIAN, Kejun 钱科军, SHANG, Xuewei 尚学伟, ZHANG, Lingtao 张令涛, DING, Hongen 丁宏恩, LI, Chun 李春, ZHAO, Lin 赵林, SUN, Pai 孙湃, LIU, Yan 刘艳] No. 86, West Chang'an Street, Xicheng District 中国北京市西城区西长安街86号, Beijing 100033Beijing 100033;No.215, Shanghai Road 中国江苏省南京市上海路215号, Jiangsu 210024Nanjing, Jiangsu 210024;No.555, Laodong Road 中国江苏省苏州市劳动路555号, Jiangsu 215004Suzhou, Jiangsu 215004;No.15, Xiaoying Rd(E)，Qinghe，Haidian District 中国北京市海淀区清河小营东路15号, Beijing 100192Beijing 100192 Disclosed are a method and system for searching a cross-regional power supply range based on a CIM model, the method comprising: creating a hash function according to the size of a power grid of the power supply voltage; mapping identification numbers of all devices in the power grid to a discrete hash table according to the hash function, using a chain address to resolve a conflict, and using the discrete hash table to form a hash topological graph of the power grid; and using the hash topological graph to search the power supply range of a specific device. The method and system can quickly locate devices within a power supply range by establishing a discrete hash table for all device resources, thus greatly reducing the amount of computation and improving the efficiency of searching within the power supply range.

[WU LI-XIN, CHEN LI-XUN, YU SHU-YU, LIU BEN-JIE, HONG XIN-YA, ZHU FANG-YI, LIN ZHI-TING, HUANG ZHE-WEI, LU XUAN-WEN, LUO YU-TING, LI YING-QIAN, WANG PEI-ZHEN, ZHONG YAN-TING, YAN SHENG-ZHOU, ZHANG JIA-HENG, ZHUANG SHAN-CONG, LI YUN-JIE, WU ZHENG-YAN, LIN JIA-ZHEN, ZHANG SU-YING, YE WEN-SHUO, WU HONG-GUANG, HUANG WEI-XIAN, XIE LI-CHUN, ZHUANG ZHI-KAI, CHEN YOU-QI, LIN PEI-YUN, HUANG ZI-LIN, SONG JIA-LIN, LIN MU-RONG, HUANG YAN-KUN, LUO YI-TING, MO KANG-NING, CHEN SI-TING, CAI JIA-JUN, HUANG YI-FENG, ZHANG LING-RONG, PAN WEN-TING, HUANG JING-ROU, KE PIN-SHENG, LIN GUAN-LIN, GAO LI-FENG, ZHAN ZHI-CHENG, NIU YUN-FANG, LI YAN-CANG, CHEN ZHENG-HAN] TW

[KUAH TENG HOCK KUAH TENG HOCK, ZHANG ZHI PAN ZHANG ZHI PAN, LEE SHUAI GE LEE SHUAI GE, LI CHUN YU LI CHUN YU, LIN YI LIN YI] An electronic device moldable to form a leadless electronic package and a method of forming the electronic device are provided. The electronic device comprises a die pad adapted for attachment of a die and a frame surrounding the die pad. A plurality of leads extend from the frame towards the die pad such that each lead has a bonding site on a top surface thereof configured for attachment of a bonding wire. The said leads include a first set of leads having bonding sites located substantially on a first plane and a second set of leads having bonding sites located substantially on a second plane that is parallel to but spaced from the first plane.

[DU, Yun, DU, Yun, CHEN, Lin, DU, Yun, CHEN, Lin, GRUBER, Andrew Evan, DU, Yun, CHEN, Lin, GRUBER, Andrew Evan, ZHANG, Chihong, DU, Yun, CHEN, Lin, GRUBER, Andrew Evan, ZHANG, Chihong, YU, Chun] Attn: International IP Administration5775 Morehouse DriveSan Diego, California 92121-1714 Techniques are described in which an indication is included to indicate a last use of an intermediate value generated as part of determining a final value is not be stored in a general purpose register (GPR). A processing unit avoids storing the intermediate value in the GPR based on the indication because the intermediate value is no longer needed for determining the final value.

[LIN PO-CHENG, HUANG PI-CHUN, HONG ZIH-HAN, CHUANG MING-HSI, LIN YI-CHUN, LEE CHIA-HSIN, CHEN CHUN-HUNG, CHANG CHAO-LIANG, ZHANG KAI-LING] TW The present disclosure provides a composition including mesenchymal stem cells, extracellular vesicles produced by the mesenchymal stem cells, and growth factor for treating liver cirrhosis. The mesenchymal stem cell-derived extracellular vesicle of the present disclosure achieves the effect of treating liver cirrhosis through various efficacy experiments.

[LIN PO-CHENG, HUANG PI-CHUN, LEE CHIA-HSIN, CHUANG MING-HSI, CHEN CHUN-HUNG, CHANG CHAO-LIANG, ZHANG KAI-LING, LIN YI-CHUN, TSAI YU-CHEN, WONG PEGGY LEH JIUNN, LIANG RUEI-YUE] TW The present invention provides a pharmaceutical composition for treating chronic stroke, involving injection via brain into the cranium of a patient having chronic stroke for six months or more; the pharmaceutical composition is a suspension at least comprising XI stem cells, an active synergistic component and a growth factor, wherein the expression level of CD34 and CD45 of the XI stem cells is 10% or less, and the expression level of CD90 and CD105 is 90% or more; the active synergistic component is an extracellular vesicle; the growth factor is at least one selected from the group consisting of HGF, G-CSF, Fractalkine, IP-10, EGF, IL-1[alpha], IL-1[beta], IL-4, IL-5, IL-13, IFN[gamma], TGF[alpha] and sCD40L. The present invention overcomes the limitations of previous cell therapy and provides a cell-based preparation that is clinically safe and therapeutically effective for chronic cerebral stroke.

[Po-Cheng Lin, Pi-Chun Huang, Chia-Hsin Lee, Ming-Hsi Chuang, Chun-Hung Chen, Chao-Liang Chang, Kai-Ling Zhang, Yi-Chun Lin, Yu-Chen Tsai, Peggy Leh Jiunn Wong, Ruei-Yue Liang] TW Zhubei City The present invention provides a pharmaceutical composition for treating chronic stroke, involving injection via brain into the cranium of a patient having chronic stroke for six months or more; the pharmaceutical composition is a suspension at least comprising TS stem cells, an active synergistic component and a growth factor, wherein the expression level of CD34 and CD45 of the TS stem cells is 10% or less, and the expression level of CD90 and CD105 is 90% or more; the active synergistic component is an extracellular vesicle; the growth factor is at least one selected from the group consisting of HGF, G-CSF, Fractalkine, IP-10, EGF, IL-1α, IL-1β, IL-4, IL-5, IL-13, IFNγ, TGFα and sCD40L. The present invention overcomes the limitations of previous cell therapy and provides a cell-based preparation that is clinically safe and therapeutically effective for chronic cerebral stroke.

[LIN PO-CHENG, HUANG PI-CHUN, LEE CHIA-HSIN, CHUANG MING-HSI, CHEN CHUN-HUNG, CHANG CHAO-LIANG, ZHANG KAI-LING, LIN YI-CHUN, TSAI YU-CHEN, WONG PEGGY LEH JIUNN, LIANG RUEI-YUE] TW The present invention provides a pharmaceutical composition for treating chronic stroke, involving injection via brain into the cranium of a patient having chronic stroke for six months or more; the pharmaceutical composition is a suspension at least comprising TS stem cells, an active synergistic component and a growth factor, wherein the expression level of CD34 and CD45 of the TS stem cells is 10% or less, and the expression level of CD90 and CD105 is 90% or more; the active synergistic component is an extracellular vesicle; the growth factor is at least one selected from the group consisting of HGF, G-CSF, Fractalkine, IP-10, EGF, IL-1[alpha], IL-1[beta], IL-4, IL-5, IL-13, IFN[gamma], TGF[alpha] and sCD40L. The present invention overcomes the limitations of previous cell therapy and provides a cell-based preparation that is clinically safe and therapeutically effective for chronic cerebral stroke.

[Po-Cheng Lin, Pi-Chun Huang, Chia-Hsin Lee, Ming-Hsi Chuang, Chun-Hung Chen, Chao-Liang Chang, Kai-Ling Zhang, Yi-Chun Lin, Yu-Chen Tsai, Peggy Leh Jiunn Wong, Ruei-Yue Liang] TW Zhubei City The present invention provides a preparation method of pharmaceutical composition for treating chronic stroke, involving injection via brain into the cranium of a patient having chronic stroke for six months or more; the pharmaceutical composition is a suspension at least comprising adipose-derived stem cells treated by cell expansion, an active synergistic component and a growth factor, wherein the expression level of CD34 and CD45 of the adipose-derived stem cells treated by cell expansion is 10% or less, and the expression level of CD90 and CD105 is 90% or more; the active synergistic component is an extracellular vesicle; the growth factor is at least one selected from the group consisting of HGF, G-CSF, Fractalkine, IP-10, EGF, IL-1α, IL-1β, IL-4, IL-5, IL-13, IFNγ, TGFα and sCD40L. The present invention overcomes the limitations of previous cell therapy and provides a cell-based preparation that is clinically safe and therapeutically effective for chronic cerebral stroke.

[Po-Cheng Lin, Pi-Chun Huang, Zih-Han Hong, Ming-Hsi Chuang, Yi-Chun Lin, Chia-Hsin Lee, Chun-Hung Chen, Chao-Liang Chang, Kai-Ling Zhang] TW Hsinchu County The present disclosure provides a method for treating liver cirrhosis by using a composition including mesenchymal stem cells, extracellular vesicles produced by the mesenchymal stem cells, and growth factors. The composition of the present disclosure achieves the effect of treating liver cirrhosis through various efficacy experiments.